An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer

被引:0
|
作者
Epperla N. [1 ]
George B. [1 ]
机构
[1] Department of Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI
关键词
Positron Emission Tomography; Bevacizumab; Standardize Uptake Value; Lynch Syndrome; KRAS Mutation;
D O I
10.1007/s12029-015-9735-y
中图分类号
学科分类号
摘要
[No abstract available]
引用
收藏
页码:206 / 209
页数:3
相关论文
共 50 条
  • [1] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [2] CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
    Aasebo, Kristine
    Dragomir, Anca
    Sundstrom, Magnus
    Mezheyeuski, Artur
    Edqvist, Per-Henrik
    Eide, Geir Egil
    Ponten, Fredrik
    Pfeiffer, Per
    Glimelius, Bengt
    Sorbye, Halfdan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?
    Selcukbiricik, F.
    Yildiz, O.
    Tural, D.
    Ozturk, M. A.
    Demir, G.
    Ozguroglu, M.
    Erdamar, S.
    Buyukunal, E.
    Mandel, N. M.
    Serdengecti, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S397 - S397
  • [4] Microenvironment targets in KRAS-mutated metastatic colorectal cancer
    Marchio, Serena
    Bartolini, Alice
    Cardaci, Sabrina
    Soster, Marco
    Corti, Giorgio
    Lamba, Simona
    Bussolino, Federico
    Cora', Davide
    Nicolantonio, Federica D.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] IMPACT OF KRAS AND BRAF GENE MUTATION STATUS ON OUTCOMES OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
    Rossi, Luigi
    Veltri, Enzo
    Zullo, Angelo
    Zoratto, Federica
    Colonna, Maria
    Longo, Flavia
    Mottolese, Marcella
    Giannarelli, Diana
    Ruco, Luigi
    Romiti, Adriana
    Barucca, Viola
    Adua, Daniela
    Baiano, Giovanni
    Giannini, Giuseppe
    Nardi, Stefano
    Lapadula, Vittoria
    Tomao, Silverio
    ANNALS OF ONCOLOGY, 2012, 23 : 108 - 108
  • [6] Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer A case report
    Capalbo, Carlo
    Marchetti, Paolo
    Coppa, Anna
    Calogero, Antonella
    Anastasi, Emanuela
    Buffone, Amelia
    Belardinilli, Francesca
    Gulino, Matteo
    Frati, Paola
    Catalano, Carlo
    Cortesi, Enrico
    Giannini, Giuseppe
    Gulino, Alberto
    CANCER BIOLOGY & THERAPY, 2014, 15 (07) : 826 - 831
  • [7] Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
    Anastasios Ntavatzikos
    Aris Spathis
    Paul Patapis
    Nikolaos Machairas
    George Peros
    Stefanos Konstantoudakis
    Danai Leventakou
    Ioannis G Panayiotides
    Petros Karakitsos
    Anna Koumarianou
    World Journal of Gastroenterology, 2017, 23 (32) : 5913 - 5924
  • [8] Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
    Artale, Salvatore
    Sartore-Bianchi, Andrea
    Veronese, Silvio Marco
    Gambi, Valentina
    Sarnataro, Carolina Silvia
    Gambacorta, Marcello
    Lauricella, Calogero
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4217 - 4219
  • [9] Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
    Ntavatzikos, Anastasios
    Spathis, Aris
    Patapis, Paul
    Machairas, Nikolaos
    Peros, George
    Konstantoudakis, Stefanos
    Leventakou, Danai
    Panayiotides, Ioannis G.
    Karakitsos, Petros
    Koumarianou, Anna
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (32) : 5913 - 5924
  • [10] BRAF-mutated metastatic colorectal cancer between past and future
    Cremolini, Chiara
    Di Maio, Massimo
    Petrelli, Fausto
    Berenato, Rosa
    Loupakis, Fotios
    Pietrantonio, Filippo
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1634 - 1635